GlycoNex and Nippon Kayaku Collaborate on Next-Generation Protease-Activated ADC GNX201 for Solid Tumors
GlycoNex, Inc. announced on March 23, 2026, a strategic collaboration agreement with Nippon Kayaku Co.,...
Nippon Kayaku
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...